FY2028 EPS Estimates for AxoGen Cut by Leerink Partnrs

AxoGen, Inc. (NASDAQ:AXGN) – Leerink Partnrs dropped their FY2028 earnings per share estimates for shares of AxoGen in a note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky now anticipates that the medical equipment provider will post earnings of $0.12 per share for the year, down from their prior estimate of $0.13. The consensus estimate for AxoGen’s current full-year earnings is ($0.33) per share.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. AxoGen had a negative net margin of 9.53% and a negative return on equity of 17.30%. The company had revenue of $47.91 million for the quarter, compared to analyst estimates of $43.27 million.

AXGN has been the subject of a number of other research reports. Raymond James began coverage on AxoGen in a report on Monday, July 1st. They set an “outperform” rating and a $13.00 target price for the company. StockNews.com raised shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Finally, JMP Securities upped their target price on shares of AxoGen from $17.00 to $20.00 and gave the stock a “market outperform” rating in a report on Friday, August 9th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $15.00.

AxoGen Stock Performance

NASDAQ:AXGN opened at $13.16 on Friday. The business’s fifty day moving average is $13.31 and its 200 day moving average is $9.44. The firm has a market cap of $575.16 million, a price-to-earnings ratio of -26.32 and a beta of 1.13. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.32 and a current ratio of 3.51. AxoGen has a 52-week low of $3.45 and a 52-week high of $15.23.

Hedge Funds Weigh In On AxoGen

A number of large investors have recently modified their holdings of the company. BNP Paribas Financial Markets grew its position in AxoGen by 8.6% during the first quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock valued at $168,000 after acquiring an additional 1,651 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of AxoGen by 8.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,650 shares of the medical equipment provider’s stock valued at $240,000 after purchasing an additional 2,204 shares during the last quarter. Lazard Asset Management LLC raised its position in AxoGen by 30.1% in the 1st quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock worth $93,000 after purchasing an additional 2,671 shares during the period. Rhumbline Advisers raised its position in AxoGen by 6.2% in the 2nd quarter. Rhumbline Advisers now owns 58,157 shares of the medical equipment provider’s stock worth $421,000 after purchasing an additional 3,380 shares during the period. Finally, nVerses Capital LLC bought a new stake in AxoGen in the third quarter worth $56,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.